The Biotechnology Innovation Organization (BIO) has named Mike Huckman, Real Chemistry’s global practice leader for executive communications, to its board of directors. Huckman becomes the first communications exec appointed to the organization’s board.
“The importance of communications to science, technology and health care has never been greater,” said John Crowley, CEO of Amicus Therapeutics and chair of the Emerging Companies section of the BIO Board of Directors, in a statement. “Mike’s decades of experience and leadership in biotech journalism and corporate communications strategy will be a perfect complement to the great work already being done at BIO and will provide the board with an important perspective.”
Before Huckman’s Real Chemistry tenure, he covered the pharma, biotech and medical device sectors at CNBC.
“After covering the life sciences as a reporter and working with biotech leaders as a consultant for decades, I know we are on the cusp of a new, revolutionary era in biotechnology,” Huckman said in the statement.
